Nephron

  • sam patrick posted an article
    SC life sciences news of note fro your reading pleasure is now live! see more

    This edition of SCBIO's semi-monthly newsletter is chock full of great information, including next week's eagerly anticipated webinar featuring top elected officials on SC's path forward from COVID, the "Slow the Spread" PSA campaign from BCBSSC and SCHA, highlights on companies stepping up in tough times, late-breaking news and more.  Read the entire thing by clicking here!

  • sam patrick posted an article
    Nephron steps up to support USC's planned reopening with donations of sanitizer see more

    Courtesy of Columbia Regional Business Report

    Nephron Pharmaceuticals Corp. is donating more than 100,000 bottles of company-manufactured hand sanitizer to the University of South Carolina as part of the West Columbia-based company's ongoing efforts to help fight COVID-19.

    The first 5,000 bottles arrived on campus today, hand-delivered by Nephron president and CEO Lou Kennedy and Nephron's new van bearing its clinical lab logo to a group of student leaders on the university’s Horseshoe.

    “No matter how tall the challenge is, Gamecocks step up,” Kennedy, a 1984 USC graduate, said in a news release. “Our company is proud to do our part to help the university make sure it is ready to welcome students, staff and faculty back to campus.”

    USC, which closed its campuses in March in response to the COVID-19 pandemic, is resuming in-person instruction in mid-August.

    “We’re grateful to Lou and Bill Kennedy and the entire team at Nephron Pharmaceuticals for this generous gift,” Bob Caslen, USC president, said. “This donation helps support the safe return of our students and employees to campus and exemplifies what the Gamecock spirit is all about: making our communities better through selfless service and caring for others.”

    The bottles bear a private label requested by the university, Kennedy said.

    Nephron develops and produces generic respiratory medication, including inhalation solutions and suspension products that can be used to treat severe respiratory symptoms associated with COVID-19.  

    In March, Nephron began making its own hand sanitizer, and previously donated 50 liters to the William Jennings Bryan Dorn Veteran Affairs Medical Center. The company added a production line in April be used in the manufacturing of bronchodilator albuterol as demand for its products soars during the pandemic.

    Last month, the company announced an expansion of its COVID-19 testing capabilities through a partnership with medical technology company One Medical. Kennedy told the Columbia Regional Business Report today that Nephron’s on-site clinical lab began testing company employees last week and plans to process samples collected during a drive-thru testing clinic June 19 and 20 at Benedict College’s football stadium.

    “We are trying to be a good partner with DHEC, a good partner with the local hospitals, and see how we can take some of the stress off of their labs for testing,” said Kennedy, who said Nephron has also developed, in partnership with Lexington Medical Center, a transport medium for nasal swabs used in the testing process.

    Nephron has hired its own nurse practitioner and installed a chief medical officer, Kennedy said. She said the department-by-department testing of employees will continue through this week.

    “The more we test, we’re going to find people that are asymptomatic, but it’s important for us to get this contact tracing thing figured out, get a baseline, get people home and get them well,” she said.

  • sam patrick posted an article
    Nephron announces new partnership see more

    Nephron Pharmaceuticals Corporation, one of the fastest growing pharmaceutical companies in the country, announced a new partnership with One Medical, a leading national digital health and primary care organization that combines 24/7 access to virtual care and digital health tools with COVID-19 testing services to businesses and employees.

    “Re-opening businesses, and getting our economy moving again, is one of our highest priorities,” said Nephron CEO Lou Kennedy, who is a member of Governor Henry McMaster’s #accelerateSC, the coordinated COVID-19 advisory team tasked with recommending economic revitalization plans for South Carolina. “Part of the new normal for businesses is testing employees to make sure the workplace is safe. We couldn’t be prouder to offer COVID-19 testing services to our employees and neighbors.”

    Kennedy and John Singerling, Chief Network Officer of One Medical and a longstanding healthcare executive based in South Carolina, are working together to make this partnership a reality, hoping that it serves as an example for businesses around the country.

    The Nephron CLIA-Certified lab has procured state-of-the-art technology for COVID-19 real-time PCR testing and serological antibody testing for its own employees, and for employees of neighboring businesses. The lab intends to integrate with One Medical’s technology platform, which is capable of supporting a comprehensive workplace reentry COVID-19 testing program. One Medical’s virtual care solutions facilitate scheduling for specimen collection and digitally documenting those test results. It also screens and evaluates clinical risk factors and symptoms and supports employer tracking and reporting needs.

    “I am very pleased to be working alongside the Nephron team to leverage One Medical’s digital health platform as a way to help get South Carolinians back to work safely,” said One Medical Chief Network Officer, John Singerling. “Currently working with over 7,000 employers nationwide has allowed One Medical to build a comprehensive workplace reentry program that is grounded in medicine and testing, and powered by our technology, which allows for seamless tracking, tracing and ongoing monitoring.”

    SARS-CoV-2 PCR tests diagnose whether a person is infected with the virus by using technology that analyzes viral genetic material. Antibody tests check blood for antibodies. If present, antibodies indicate a person has been previously or is currently infected by the virus.

     

    Nephron Pharmaceuticals Corporation has been on the frontlines of the nationwide COVID-19 response. The West Columbia-based company develops and produces safe, affordable generic inhalation solutions and suspension products that can be used to treat severe respiratory distress symptoms associated with COVID-19. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. These products are used, many times, to sedate patients and keep them comfortable when health care professionals place them on ventilators in the fight against the virus.

  • sam patrick posted an article
    Nephron seeks to stem coronavirus concerns with expanded offerings see more

    In response to the novel coronavirus pandemic, West Columbia-based Nephron Pharmaceuticals Corp. has asked the Food and Drug Administration for permission to add up to six filling lines to ramp up its production of sterile respiratory medication.

    Nephron CEO Lou Kennedy said she spoke with the FDA on Tuesday morning and is “waiting to hear back.” Kennedy also said Nephron will begin making its own hand sanitizer as early as this week.

    Nephron, which CEO Lou Kennedy said is one of two companies in the U.S. that produce 98% of the nebulizer solutions used in hospitals or sold in retail outlets, relocated to South Carolina from Florida in 2014.

    “We didn’t move all the equipment right away,” moving an additional six filling lines to South Carolina in 2019, Kennedy said. She said she had been in discussion with the FDA for permission to bring those machines online. A meeting had been scheduled for March 22 before she made another request Tuesday.

    West Columbia-based Nephron has asked for FDA approval to add up to six filling lines for its respiratory medication manufacturing. CEO Lou Kennedy also announced the company will begin making hand sanitizer this week. (Photo/File)

    The eight filling lines currently being used in production of the inhalation solutions Nephron makes typically produce 80 to 85 million doses a month “on a regular basis” and are capable of making up to 110 million monthly doses, Kennedy said.

     

    “As of yesterday, we had orders on the books for 87 million, so already a month’s worth,” Kennedy said. “For the last two weeks, those orders have been running about 48% higher than we would normally see. … We do have backstock that we’ve built up in inventory, (but) that won’t last forever.”

    To maximize Nephron’s 24-hour, seven-day-a-week production schedule, Kennedy said the company has begun providing in-house child care. Children are provided food, and already stringent cleaning efforts have been “tripled,” Kennedy said. She said the same methods used to maintain sterile facility conditions, including the use of a fogging machine and wiping down surfaces with isopropyl alcohol and hydrogen peroxide, are being deployed in the day care.

    “We’re really good at cleaning here, because we only make sterile drugs,” Kennedy said. “I’m very confident about making a clean environment for these children.”

    During a conference call Tuesday, Kennedy also said Nephron has received FDA approval to begin making its own hand sanitizer and ordered supplies to do so on Monday.

    “We will take care of the Nephron family first, and after we do that, we will look at should we go through churches, the Salvation Army, how can we help the community, and/or commercial production,” she said. “I’ve had at least six requests from various sales reps across the country. Hospitals are asking can we make that hand sanitizer for them.”

    The plan is to produce 50-liter batches of a strong, FDA recipe without fragrances or other diluting agents, Kennedy said. She said she will gift what is left over from the first batch, after Nephron employees and their families have been served, to local charities.  

    Kennedy said as early as December, Nephron began taking stock of things such as the resin used to make vials of its liquid medication as well as its supply of active pharmaceutical ingredients. “We are fortunate that we have more than a year’s supply of that (API) on hand,” she said.

    Nephron makes bronchodilators including albuterol used to treat respiratory illnesses such as bronchial asthma, pneumonia, emphysema and croup. It also manufactures Pocket Nebs, which are portable, battery-charged nebulizers.

    Novel coronavirus can cause cough, shortness of breath and breathing difficulties. Severe infections can lead to complications including pneumonia, according to the World Health Organization.

    Increased product demand during cold, cough and allergy season, as well as past experience with respiratory illnesses including SARS and H1N1, have made the company ever-vigilant, Kennedy said.

    “We make sure to be very rock-solid in our preparation to accommodate the needs of America,” she said.

    Kennedy said hiring and training has already begun in anticipation of FDA approval of the additional filling lines.

    “We have the people to be able to ramp that up right now,” she said. “ … If we don’t get our hands wrapped around this quickly, meaning we squelch the spread, get control of the spread, it’s going to be a long, hard road. But it’s easily solved if the FDA allows me to ramp up the five or six other lines that I brought here from Florida.”

  • sam patrick posted an article
    Nephron partnership helps patients receive anesthetics faster see more

    A new partnership between Nephron Pharmaceuticals Corp. and National Medical Products Inc. will help provide more patients with a quick and simple delivery of anesthetic medications, according to a news release from Nephron.

    National Medical Products is the developer of the single-use, subcutaneous J-Tip Needle-Free Injector. Hospitals which use the injector will now be able to use Nephron-developed technology in a Luer lock syringe, buffered and pre-filled with lidocaine, to fill it.

    “This new partnership is a huge win for patients, and we are extraordinarily excited to announce it,” Lou Kennedy, CEO of West Columbia-headquartered Nephron, said in the release. “Working together with the developers of J-Tip, we are making sure that the delivery of anesthetic medications is safe, easy-to-use and virtually pain-free, because patients deserve nothing less.”

    California-based National Medical Products, established in 2001, refined a jet-injection technology previously used by the military for vaccine delivery to create a self-contained injector that uses compressed carbon dioxide to provide an anesthetic effect in one to two minutes, according to the release. The injector is most commonly used before procedures such as IV insertions and blood draws.

    Nephron said the companies hope the partnership will help reach more patients.

  • sam patrick posted an article
    USC Research partnerships generating big impact for state see more

    When the University of South Carolina’s Office of Economic Engagement (OEE) first launched six years ago, its goal was to build relationships between researchers and industry partners. True to its mandate, the university has forged ties with global industry giants and is driving hundreds of millions of dollars into the state’s economy.

    The OEE, with its corporate and government partners, has created over $790 million in indirect economic impact since its founding in 2013, using a standard economic development analysis that examines both direct and indirect economic benefits generated through the office. The figure includes ongoing industry partner investments along with grant generation, software gifts, and new job creation.

    “Thanks to the vision of President Harris Pastides, OEE has had a swift economic impact on our state,” said University of South Carolina president Robert Caslen. “We look forward to building more research partnership opportunities, and providing our students with the skills and expertise needed for success in high-tech careers.”

    The OEE serves as the convergence point for private industry, government and the university. In addition to connecting industry partners with the university’s intellectual capital, it also leads technology commercialization efforts, fosters entrepreneurship and start-ups, supports research centers, and grows existing collaborations.

    “The tremendous success we’ve had in such a short period of time is a testament to the quality of research taking place here at the University of South Carolina,” said OEE Executive Director Bill Kirkland. “We are in the top one percent of patent-producing universities in the world, and innovative industry leaders know that South Carolina is the place to be.”

    Ongoing research partnerships include a wide range of companies and federal agencies, from advanced computing, aerospace and automotive, to health care. They include: IBM, Boeing, NASA, Samsung, Siemens, Yaskawa, Capgemini, Prisma Health, Nephron, TIGHITCO and more.

    OEE supported research centers include:

    Three labs located at the McNAIR Aerospace Research Center on Catawba Street:

    The IBM IOT Industrial Innovation Center (2018). The only university based IBM lab of its kind in North America, the lab uses cloud data to develop new technolgoies to help American manfacturers improve their operations.

    The Digital Transformation Lab (2018). The 15,000 square-foot lab serves as a research showplace where projects with an array of real-world industrial and consumer applications are on display—from robotics, visual inspection, and autonomous drones to smart home appliances.

    The Center for Predictive Maintenance. Researchers and students from four university departments support the U.S. Army Aviation program Using cloud-based technology and machine learning, researchers and students use the technology to conduct detailed analyses, identify potential defects or problems, and recommend specific solutions to improve maintenance for combat helicopters.

    Siemens Healthineers Innovation Think Tank (ITT) Lab (2019). The ITT Lab is the first of its kind affiliated with a U.S. university.  The lab will be an innovation hub where participants including researchers, faculty members, and students can think outside the box to solve issues in healthcare, artificial intelligence, robotics, and information technology alongside industry innovation leaders. 

    The AI Institute (2019). The new institute advances state-of-the-art AI applications in fields like health care, education, social sciences, communications, advanced manufacturing, autonomous transportation, and personalized security, while also examining the ethics and societal impact of advancing technologies.

  • sam patrick posted an article
    Nephron, Clemson partner to meet hospital needs see more

    Nephron Pharmaceuticals Corporation is partnering with Clemson University to create a robotic solution for syringe-filling automation to enhance sterile manufacturing in the pharmaceutical production process and keep up with growing hospital demands.

    “We are excited about our new partnership with Clemson and we cannot wait to get started,” said Nephron CEO Lou Kennedy. “Working together with Clemson’s world-class researchers and engineers we can ensure that the pharmaceutical manufacturing process remains safe and we can deliver life-saving drugs to patients and hospitals across the country.”

    The university’s newest strategic partner is turning to Clemson to harness the power of technology for more efficient processes. To do so, Nephron is enlisting the expertise of the College of Engineering, Computing and Applied Sciences professor and researcher Yue “Sophie” Wang and mechanical engineering doctoral student Brandon Delspina and mechanical engineering master’s student Yu “Gloria” Zhang.

    Their robotics research for syringe automation will support the Nephron 503B Outsourcing Facility, a cGMP manufacturer providing sterile, pre-filled medications to address persistent drug shortages in hospitals and medical facilities across America.

    Based in West Columbia, Nephron is a certified woman-owned business and one of the fastest-growing companies in South Carolina. This is Nephron’s first partnership with the university and was developed through External Affairs’ Office of Corporate Partnerships and Strategic Initiatives at Clemson University.

    “When the External Affairs’ Office of Corporate Partnerships and Strategic Initiatives approached us about this project we were excited to get involved,” said Wang, associate professor of mechanical engineering. “Our work in robotics can have a tremendous impact on individuals across the country and we are looking forward to working on this because of its benefits for the many patients Nephron serves.”

    “Industry needs are changing at a rapid rate and Clemson is equipped to support companies like Nephron. Together, we have created a mutually beneficial project to enhance their capabilities while providing the university’s students with unique, hands-on research experience,” said Angie Leidinger, vice president for External Affairs. “This partnership is a testament to the work happening at Clemson and we’re looking forward to this collaboration, which will advance their business and benefit South Carolinians.”

  • sam patrick posted an article
    Nephron advances let it deliver supplies to hospitals faster than ever see more

    Nephron Pharmaceuticals Corp., headquartered in West Columbia, has announced the implementation of a microbial testing tool that the generic respiratory medication manufacturer says will help it deliver medical supplies to hospitals faster than ever.

    Growth Direct, developed by Massachusetts-based lab equipment supplier Rapid Micro Biosystems, automates the incubation, colony counting and data entry of microbial environment testing, according to a Nephron news release. The tool also detects microbial growth 50% faster than human eye.

    “We work hard, day in and out, to deliver safe, effective and affordable life-saving medications as efficiently as possible,” Nephron CEO Lou Kennedy said in the release. “Automating our microbial monitoring process allows us to produce safer drugs faster and decreases the shortage of opioid-free pain medication currently facing our nation’s hospitals.”

    Growth Direct will allow Nephron’s 503(b) outsourcing division, which produces pre-filled sterile syringes and IV bags, to deliver medical supplies more quickly, the release said.

    “We're excited that Nephron Pharmaceuticals Corp. has joined the growing list of global pharmaceutical manufacturers who are upgrading and automating their QC Microbial testing methods with the Growth Direct,” Rapid Micro Biosystems CEO Rob Spignesi said. “And we are proud to help Nephron Pharmaceuticals reduce the shortage of important drugs that help make surgery safer and less painful for patients across the country.”

  • sam patrick posted an article
    SCBIO and Nephron Pnarma executive Lou Kennedy honored by E&Y see more

    WEST COLUMBIA, S.C., June 28, 2019 /PRNewswire/ -- Ernst & Young (EY) honored Nephron Pharmaceuticals President and CEO Lou Kennedy as Health Care Entrepreneur of the Year for the Southeast on Thursday during a gala at the Coca-Cola Roxy in Atlanta. Kennedy, who is Chairman of the South Carolina Chamber of Commerce and of SCBIO, and a nationwide leader in health care, will now compete for the EY national entrepreneur of the year award in November.

    "I am grateful that EY recognizes the hard work our team does every day to deliver safe, effective and affordable drugs to patients, focusing on opiod-free pain treatment," said Kennedy. "As president of a global leader in life-saving drug manufacturing, I hope this award serves as a reminder that women are leading the fight to improve lives across the country and world, and at Nephron, like so many women-owned businesses, we are just getting started."

    Business leaders consider the EY entrepreneur of the year award to be one of the highest professional honors a business owner can earn. The award identifies leaders of fast-growth companies who are making a difference for their communities and beyond through innovation. 

    Nephron is a certified woman-owned business, as recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises. The certification gives Nephron enhanced visibility and a competitive edge.

    The Nephron workforce is forty-four percent women, holding the majority of all advanced degrees at the company. Additionally, women hold key management roles in various departments throughout Nephron, such as Quality Assurance, Chemistry and Microbiology, Regulatory Compliance, Human Resources, Training, R&D Engineering, and Product Development.

    About Nephron
    Nephron Pharmaceuticals Corporation develops and manufactures safe, affordable generic inhalation solution and suspension products specializing in Blow-Fill-Seal technology. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.

  • sam patrick posted an article
    Nephron CEO and SCBIO Chair Lou Kennedy interviewed on the growth and success of her organization. see more

    Nephron Pharmaceuticals Corporation, located in West Columbia, South Carolina, is a global leader in manufacturing generic respiratory medications and contract manufacturing. Through its innovative approach to sterile manufacturing, Nephron also provides patients access to affordable, high-quality medications. Nephron’s sterile injectables program helps with the drug shortages that hospital across the country are facing.

    Nephron has grown from 400 employees in 2018 to now over 1,000.  A certified woman-owned business, Nephron is recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises.  CEO Lou Kennedy leads the dyunamic organization as well as chairs SCBIO, the life sciences organization for the Palmetto State.  Enjoy this interview with Lou Kennedy, courtesy of MidlandsBiz:  https://whosonthemove.com/lou-kennedy-nephron-pharmaceuticals/

  • sam patrick posted an article
    Nephron initiates EDI through Global Healthcare Exchange see more

    Nephron Pharmaceuticals Corporation initiated Electronic Data Interchange (EDI) ordering through the Global Healthcare Exchange, LLC (GHX) platform, accessible immediately.

    Joining GHX allows Nephron customers to purchase products on the FDA drug shortage list in one simple step. This platform enables purchasers to select products from multiple vendors in one place, rather than logging in to the Nephron online ordering system.  Utilizing the GHX cloud-based platform helps to reduce manual work and provides real-time data to view and validate order information. Nephron and its customers are working in real time, using all available data to streamline each process.

    “Nephron is constantly trying to improve the customer experience,” said Hank Jibaja, Chief Information Officer at Nephron. “We believe utilizing the GHX platform will decrease the time required from the hospital or ordering staff.”

    Nephron products including Sodium Bicarbonate, Phenylephrine, Labetalol and more are available for purchase through the GHX platform.

    Hospitals and surgery centers may contact Nephron toll free at 1-800-443-4313, or via email at customerservice@nephronpharm.com.

     

    About Nephron

    Nephron 503B Outsourcing is a division of Nephron Pharmaceuticals Corporation. This division produces pre-filled sterile syringes and IV bags for hospitals and surgery centers across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration as a sterile manufacturer of generic respiratory medications along with an Outsourcing Facility providing equal sterility and quality. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.

    About GHX

    Global Healthcare Exchange, LLC (GHX) is a healthcare business and data automation company, empowering healthcare organizations to enable better patient care and maximize industry savings using its world-class cloud-based supply chain technology platform. GHX brings together healthcare providers, manufacturers and distributors in North America, and Europe, who rely on proven healthcare-focused technology and comprehensive data to automate business processes and make more informed, timely and fact-based decisions. Solutions span procurement and accounts payable automation, contract and inventory management, vendor credentialing and management, business intelligence, payment management and other supply chain-related tools and services. For more information, visit www.ghx.com and The Healthcare Hub.

  • sam patrick posted an article
    Nephron CEO Lou Kennedy honored with national award see more

    Nephron Pharmaceuticals President and CEO Lou Kennedy was honored on Thursday by the National Association of Manufacturers (NAM) with an award for outstanding leadership in manufacturing.  Ms. Kennedy is also the Board Chair of South Carolina's life sciences organization, SCBIO.

    NAM recognized Kennedy at its Manufacturing Institute’s STEP Ahead Women’s Initiative. One of NAM’s largest annual events, the STEP Ahead Award celebrates the achievements of women in manufacturing who inspire the next generation to follow in their footsteps.

    “Nephron is a global leader in pharmaceutical manufacturing, and I am grateful to NAM for recognizing the great work of our team of professionals that delivers safe, effective and affordable medications to patients across the world,” said Kennedy.

    Nephron is a certified woman-owned business, as recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises. The certification gives Nephron enhanced visibility and a competitive edge.

    Nephron’s workforce is forty-four percent women, holding the majority of all advanced degrees at the company. Additionally, women hold key management roles in various departments throughout Nephron, such as Quality Assurance, Chemistry and Microbiology, Regulatory Compliance, Human Resources, Training, R&D Engineering, and Product Development.

     

    About Nephron

    Nephron Pharmaceuticals Corporation develops and manufactures safe, affordable generic inhalation solution and suspension products specializing in Blow-Fill-Seal technology. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.

  • sam patrick posted an article
    Nephron Pharmaceuticals continued support of educational opportunities by announcing scholarships see more

    The South Carolina Governor’s School for the Arts and Humanities received a $13,800 gift from Nephron Pharmaceuticals to support meal plan scholarships for Midlands students attending the school’s residential high school program.

    “Nephron Pharmaceuticals Corporation is so proud to support arts education in our state. I have seen first-hand the impact of an arts education on the mind of a scientist, and it’s a beautiful thing. Look at a trained violinist and a pharmaceutical product developer. Both pursuits require repetition, dedication, critical thinking and the ability to solve a problem from a variety of angles,” said Lou Kennedy, CEO of Nephron Pharmaceuticals. “At Nephron, we’re always looking for critical thinkers and problem solvers, and that is why we are so passionate about supporting the arts as well as the sciences. We are proud to be a sponsor the South Carolina Governor’s School for the Arts and Humanities, and I encourage my fellow CEOs to support arts education across our state. We’re playing the long game here, and we aim to win.”

    “While the Governor’s School for the Arts is a state-funded and tuition-free public high school, there are still meal plan fees that would present a financial barrier for many families if it weren’t for the support of our generous individual and corporate donors,” said Dr. Cedric Adderley, S.C. Governor’s School for the Arts and Humanities president. “Thanks to Nephron Pharmaceuticals, our emerging artists can pursue their dreams without worrying about costs.”

    While tuition is free for all students attending for the full school year, about 30 percent of Governor’s School for the Arts students receive financial assistance from the Governor’s School for the Arts Foundation to pay for the $3,500 meal plan each year. This plan includes three meals per day for seven days per week during the nine-month school year. Nephron’s gift will provide meal plan scholarships to four Midlands students during the 2018-2019 school year.

    Currently, 52 of the Governor’s School for the Arts’ 236 high school students are from the Midlands region, including Calhoun, Fairfield, Kershaw, Lexington, Orangeburg, Richland, Saluda, and Sumter counties. These students were selected based on their talents exhibited through a comprehensive application and audition process.

    To learn more about the S.C. Governor’s School for the Arts & Humanities, follow @SCGSAH on social media and visit http://www.scgsah.org.

  • sam patrick posted an article
    Nine Nephron employees to earn their Community Pharmacy Technician certificates at no cost... see more

    Nephron Pharmaceuticals Corp. is partnering with Apprenticeship Carolina to provide nine Nephron employees a chance to earn a Community Pharmacy Technician certificate at Midlands Technical College.  Apprenticeship Carolina is a division of the S.C. Technical College SystemRead on for full details.

  • sam patrick posted an article
    Nephron announces 5% salary increases thanks to tax cuts law see more

    WEST COLUMBIA, S.C. – Nephron Pharmaceuticals Corporation (Nephron) CEO Lou Kennedy today announced five percent increases for all employees with the exception of commissioned employees.  The raises are a direct result of the Tax Cuts and Jobs Act that was signed into law last week by President Donald Trump.

    “We are excited that the Tax Cuts and Jobs Act has given us an opportunity to recognize their hard work and sacrifices with well-deserved raises”, said Lou Kennedy, CEO of Nephron.

    Elected officials – including The Honorable Henry McMaster, Governor of South Carolina, U.S. Senator Lindsey Graham, Congressman Joe Wilson, state legislators and local elected officials – joined Kennedy and Nephron employees for today’s announcement celebration at the company’s West Columbia headquarters. Both of South Carolina’s U.S. Senators and six of the state’s seven members of the U.S. House of Representatives voted in favor of the Tax Cuts and Jobs Act.

    "I am grateful that the tax cuts House Republicans worked so hard to pass have had an immediate impact in the district,” said Congressman Joe Wilson. “I congratulate Lou and Bill Kennedy, as well as Nephron's entire team, on today’s announcement, and I wish them continued success.”

    Nephron is a manufacturer of respiratory and compounded 503B outsourcing medications that employs 640 people in West Columbia. The company, which launched 34 new products in 2017, recently announced a $12.5 million expansion and expects to add 125 additional employees by June 2018.

    Fifty percent of Nephron employees attended South Carolina universities or technical colleges. Nephron founder Bill Kennedy and CEO Lou Kennedy are University of South Carolina graduates and South Carolinians. The company is part of the life sciences industry in the State.  This industry has a total $11.4 billion annual impact on the State economy.

    For more information about Nephron, visit http://www.nephronpharm.com.